3-hydroxykynurenine has been researched along with Coronary Disease in 1 studies
3-hydroxykynurenine: RN given refers to cpd without isomeric designation
3-hydroxykynurenine : A hydroxykynurenine that is kynurenine substituted by a hydroxy group at position 3.
hydroxykynurenine : A hydroxy-amino acid that is kynurenine substituted by a single hydroxy group at unspecified position. A "closed" class.
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In plasma from 3035 patients undergoing coronary angiography for suspected coronary heart disease, we investigated if plasma concentrations of any metabolites in the kynurenine pathway, which depend on PLP as cofactor, may serve as metabolic marker(s) of vitamin B-6 status." | 7.77 | Low plasma vitamin B-6 status affects metabolism through the kynurenine pathway in cardiovascular patients with systemic inflammation. ( Bleie, O; Ebbing, M; Midttun, O; Nilsen, RM; Nygård, O; Ringdal Pedersen, E; Schartum-Hansen, H; Ueland, PM; Ulvik, A, 2011) |
| " In plasma from 3035 patients undergoing coronary angiography for suspected coronary heart disease, we investigated if plasma concentrations of any metabolites in the kynurenine pathway, which depend on PLP as cofactor, may serve as metabolic marker(s) of vitamin B-6 status." | 3.77 | Low plasma vitamin B-6 status affects metabolism through the kynurenine pathway in cardiovascular patients with systemic inflammation. ( Bleie, O; Ebbing, M; Midttun, O; Nilsen, RM; Nygård, O; Ringdal Pedersen, E; Schartum-Hansen, H; Ueland, PM; Ulvik, A, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Midttun, O | 1 |
| Ulvik, A | 1 |
| Ringdal Pedersen, E | 1 |
| Ebbing, M | 1 |
| Bleie, O | 1 |
| Schartum-Hansen, H | 1 |
| Nilsen, RM | 1 |
| Nygård, O | 1 |
| Ueland, PM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised Double Blind Study of the Effects of Homocysteine Lowering Therapy on Mortality and Cardiac Events in Patients Undergoing Coronary Angiography[NCT00354081] | Phase 3 | 3,096 participants (Actual) | Interventional | 1999-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for 3-hydroxykynurenine and Coronary Disease
| Article | Year |
|---|---|
Low plasma vitamin B-6 status affects metabolism through the kynurenine pathway in cardiovascular patients with systemic inflammation.
Topics: Adult; Aged; C-Reactive Protein; Coronary Disease; Female; Humans; Inflammation; Kynurenine; Male; M | 2011 |